Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Here are two important insights from that call that should excite investors ... of its fourth-quarter and full-year 2024 earnings report. Even though Novo Nordisk is still leading the GLP-1 ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Bullish option flow detected in Novo Nordisk (NVO) with 6,619 calls trading, 1.5x expected, and implied vol increasing over 2 points to 42.66%.

At quarterly earnings in February, Novo said that it had increased supplies of Wegovy to the U.S. market and said its fiscal guidance for the year reflected this. Total weekly Wegovy prescriptions ...

Ladies and gentlemen, welcome to the Novonesis Full Year Financial Statement for 2024 and Annual Report 2024 Conference Call. I'm Youssef ... revenue growth and earnings accretion for Novonesis.

Novo Nordisk NVO shares have lost 15.2% so ... which was provided on the third-quarter earnings call. NVO faced a major setback in December 2024, after the 22.7% weight loss observed in obese ...

Though Novo Nordisk's financial performance was strong, it's worth pointing out several other things management mentioned during its earnings conference call with analysts. Here are two important ...